



1-21-09

\$7w

Docket No.: NY-MSI 203-US
(PATENT)

Supplemental Information Disclosure Statement

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EM 155745465 US, on the date shown below in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450.

Dated: 1/16/09 Signature: Fani Malikouzakis
(Fani Malikouzakis)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Edward F. Ikeguchi et al.

Application No.: 10/667,848

Confirmation No.: 1385

Filed: September 22, 2003

Art Unit: 4143

For: SYSTEM AND METHOD FOR
CONTINUOUS DATA ANALYSIS OF
AN ONGOING CLINICAL TRIAL

Examiner: R. J. RAJ

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 C.F.R. § 1.98(a)(2) accompany this statement.

Applicants have become aware of the following documents, cited in an International Search Report issued October 6, 2008, during the prosecution of International Application No. EP 04 78 4687, which corresponds to the above referenced application, and in accordance with 37 C.F.R. § 1.97(c) and (e)(1) or (b)(3), hereby submit these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the International

Search Report and of each document required under 37 C.F.R. § 1.98(a)(2) cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 C.F.R. § 1.97(c)).

I hereby certify, pursuant to 37 C.F.R. § 1.97(e)(1), that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0624, under Order No. NY-MSI 203-US (10406788).

Dated: 1/16/09

Respectfully submitted,

By 

C. Andrew Im

Registration No.: 40,657

FULBRIGHT & JAWORSKI L.L.P.

666 Fifth Avenue

New York, New York 10103

(212) 318-3000

(212) 318-3400 (Fax)

Attorney for Applicant